Published Aug 14, 2026
Aura Biosciences H1 FY2026: Phase 3 Enrolled, Eyes Only - and the Cash Math Just Got Better
In-depth research on AURA covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
5,650 words25 min read
Read report